Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19917246 | 1.00 | KDM4E (0.32) | KDM4EMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL16317653 | 1.00 | KDM4E (0.32) | KDM4EMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL15012994 | 0.88 | KDM4E (0.33) | KDM4EMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL16449929 | 0.88 | KDM4E (0.33) | KDM4EMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL19286312 | 0.88 | KDM4E (0.33) | KDM4EMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL24032033 | 0.82 | MEN1 (0.33) | KDM4EMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL16317619 | 0.81 | KDM4E (0.32) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL13150731 | 0.81 | KCNA5 (0.33) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL17470036 | 0.78 | HTR2A (0.32) | — | |
| SCHEMBL13421750 | 0.78 | HTR2A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975837-B2 | Method for synthesizing optically active carbonyl compounds | BASF SE (DE) | 2018-05-22 | — | — | US | disclosed |
| US-20070213540-A1 | Process for the hydrogenation of imines | DEGUSSA AG (DE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213540-A1 | Process for the hydrogenation of imines | KCNH3, KCNH2, KMO | KDM4E 1507/4885MEN1 1490/4885ALDH1A1 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.